Tom 7, Nr 3 (2014)
Artykuł przeglądowy
Opublikowany online: 2014-10-23
Wyświetlenia strony
462
Wyświetlenia/pobrania artykułu
1415
Indukcja tolerancji immunologicznej w hemofilii powikłanej inhibitorem w świetle nowych badań
Journal of Transfusion Medicine 2014;7(3):97-101.
Streszczenie
Brak
Referencje
- Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet. 1992; 339(8793): 594–598.
- Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003; 9(4): 418–435.
- Hay CR. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia. 1998; 4: 558–563.
- Kempton CL, Soucie JM, Miller CH, et al. In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost. 2010; 8(10): 2224–2231.
- Eckhardt CL, van der Bom JG, van der Naald M, et al. Surgery and inhibitor development in hemophilia A: a systematic review. J Thromb Haemost. 2011; 9(10): 1948–1958.
- Coppola A, Di Minno MND, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol. 2010; 150(5): 515–528.
- Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2012; 19(1): e1–e47.
- Batorova A, Morongova A, Tagariello G, et al. Challenges in the management of hemophilia B with inhibitor. Semin Thromb Hemost. 2013; 39(7): 767–771.
- Beutel K, Hauch H, Rischewski J, et al. ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hamostaseologie. 2009; 29(2): 155–157.
- DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007; 13 Suppl 1: 1–22.
- Astermark J, Morado M, Rocino A, et al. EHTSB. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia. 2006; 12(4): 363–371.
- Hay CRM, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006; 133(6): 591–605.
- Nakar C.T., Manco-Johnson M.J., Lail A. i wsp. Prompt immune tolerance induction at inhibitor diagnosis regardless of titer may increase overall success in hemophilia A with inhibitors: experience of two US centers. 55 th ASH Meeting, 2013; abstr. 575.
- Hay CRM, DiMichele DM. International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012; 119(6): 1335–1344.
- Athale AH, Marcucci M, Iorio A. Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. Cochrane Database Syst Rev. 2014(4): CD010561.
- Kreuz W., Escuriola-Ettingshausen C. Observational Immune Tolerance Induction (ObsITI) research program. www.obsiti.com.
- Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis. 2005; 16 Suppl 1: S27–S31.
- Gensana M, Altisent C, Aznar JA, et al. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII. Haemophilia. 2001; 7(4): 369–374.
- Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica. 2003; 88(6): EREP05.
- Orsini F, Rotschild C, Beurrier P, et al. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica. 2005; 90(9): 1288–1290.
- Gringeri A, Musso R, Mazzucconi MG, et al. RITS-FITNHES Study Group. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia. 2007; 13(4): 373–379.
- Greninger DA, Saint-Remy JM, Jacquemin M, et al. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia. 2008; 14(2): 295–302.
- Kurth M, Puetz J, Kouides P, et al. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost. 2011; 9(11): 2229–2234.
- Valentino LA, Recht M, Dipaola J, et al. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A. Haemophilia. 2009; 15(3): 718–726.
- Van Ve, Peters M, van de, et al. Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review. Br J Haematol . : 1–11.
